handbook 2015 - genesis conference · laurence is responsible for managing gsk’s venture...

genesis 2015Handbook

2015

60 years ago, British researchers co-discoveredthe structure of DNA. Today they continue tomake world-changing discoveries. Unlock yourglobal business potential with UK innovation.

gov.uk/uktiDNA (deoxyribonucleic acid) molecule

Genesis 2015 Sponsors

Supporters

Gold Sponsors

Bronze Sponsors

Silver Sponsors

Media Partners

60 years ago, British researchers co-discoveredthe structure of DNA. Today they continue tomake world-changing discoveries. Unlock yourglobal business potential with UK innovation.

gov.uk/uktiDNA (deoxyribonucleic acid) molecule

Media Supporters

3

ContentsWelcome 6

Keynote Speakers 7 Speaker Profiles 8 - 25

Programme 26 - 27

Floor Plan and Exhibitor List 28 - 29 The Source Lounge 32 Exhibitors 34 - 43

Corporate Patron

Corporate Sponsors

Partners

sponsors

Catalysing the power of the golden triangle

“Life sciences is the most exciting and rewarding sector to invest in” Dr Eliot Forster, CEO, Immunocore, and Executive Chair, MedCity

Find out how we can help you do business across the greater south east of Englandmedcityhq.com

Find out more about opportunities for investors and emerging companies at angelsinmedcity.org.uk

From the Francis Crick Institute and the Cell Therapy Catapult to Imperial West and AstraZeneca’s Global R&D Centre, the life sciences constellation of the London-Oxford-Cambridge golden triangle is in a period of unprecedented ambition.

Established by the Mayor of London with the capital’s three academic health science centres, MedCity is championing entrepreneurship and investment to build on the region’s global reputation as a world-leading life sciences cluster.

Early-stage life sciences companies offer exciting opportunities for investors to make excellent returns and make a difference to the health and well-being of thousands. Angels in MedCity runs regular free workshops for potential investors to understand the sector, identify strong propositions and connect with angel syndicates led by sector experts.

Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences.

MedCity_Adverts_Genesis_Conference_2015_AW.indd All Pages 05/11/2015 14:29

The overarching theme of this year’s conference is ‘Taking Bio-Innovation to a Global Market’. Our programme addresses this with content covering the three main pillars for growth in the sector; technology, finance and people.

The One Nucleus team and I know you will make full use of the presentations, debate, networking and the exhibition hall to catch up with old friends and make some new ones, update yourselves on trends in the sector and create and scope out new business opportunities. Please do not hesitate to talk with any one of the One Nucleus team. We are here to help you make the most of your time at Genesis and ensure you leave us with a spring in your step and light of heart knowing that you have just had a hugely productive day!

The One Nucleus membership continues to grow and we remain the largest membership organisation for the sector in Europe (by some distance, with over 470 organisations as members). The majority of our members are based in Cambridge and London with many of them here today.

Genesis continues to be a truly international networking exhibition that we intentionally evolve year on year. New for 2015 we have an intentionally reformatted Exhibition Hall affording all stands greater visibility, more specific Source Hubs (after the success of our inaugural Source Lounge last year) and 1-2-1 clinic options on (i) Get Ready for JP Morgan 2016 (ii) Outsourcing R&D and (iii) Preparing for Start-Up and High Growth. We have updated the core programme to include an additional Plenary Panel which increases the programme content and dynamic further as does the addition of the Farr Institute stream which brings in the health

informatics elements of the sector. We continue to have our partnering system for you and are delighted that the Life Sciences Hub Wales is our new partner for this. You can find partnering in the Fleming Room.

Last year we brought you the first ever ‘Genesis Fringe’ – a range of great events and activities taking place before and after Genesis that One Nucleus is delighted to support and promote. We got such great feedback from Genesis guests, who were able to maximise the benefits of their trip, that we have brought it back for 2015. I hope you have experienced, or plan to experience a Genesis Fringe event during your time in London. Do check out page 29 for details.

We are also continuing with the much appreciated (by us and guests) collaboration with the SCRIP team on Genesis. We have worked incredibly closely together on key elements of the day, evolving it to enhance the knowledge-sharing opportunities for you. The insights gained over the day will fuel the much anticipated SCRIP-One Nucleus Plenary Debate providing the panellists and delegates with the chance to share their suggestions to enhance success at individual, company and sector wide level.

Finally and very importantly I would like to extend a big ‘thank you’ to all our Sponsors, supporters and collaborators for helping to make Genesis happen.

I wish everyone an excellent event and thank you for taking part.

welcomeDear Genesis Participant,

Welcome to our 15th Annual Genesis Conference

6 welcome

George Freeman MPMinister for Life Sciences George was elected to Parliament in 2010 after a 15 year career across the life sciences sector, in particular working with hospitals, clinical researchers, patient groups, and biomedical research companies to pioneer novel healthcare innovations.

Following his election to Parliament in 2010, George served as PPS to the Minister of State for Climate Change. He was appointed Government Adviser on Life Sciences in July 2011, working closely with the Department of Health and coordinating the Government’s Life Science and Innovation, Health and Wealth Strategies (2011), and the Agri-Tech Industrial Strategy (2013). Following that, he was appointed to the post of Prime Minister’s UK Trade Envoy.

On July 15 2014, George was appointed as Minister for Life Sciences, a Parliamentary Under-Secretary of State at the Department of Health and Department of Business, Innovation and Skills. His mission is to make the UK the best place in the world to discover and develop 21st Century healthcare innovations.

Mike Ward Chief Content Officer, SCRIP Intelligence and Datamonitor

Mike has been writing, analysing and commenting on the life sciences industry for the past 30 years. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry’s key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year.

Richard Mason Head of Johnson & Johnson Innovation, London Richard joins Johnson & Johnson Innovation from XO1-Limited where he served as CEO before it was acquired by Janssen earlier this year. Richard is a physician by training and has had a number of senior roles in innovative biotechnology companies. Richard specializes in transforming companies through collaborations and deal-making, including multiple acquisitions. Richard earned his MBA from The Judge Business School University of Cambridge.

7keynote speakers

Eva-Lotta Allan CBO and Board Director, Immunocore Eva-Lotta Allan has over two decades of business development experience from the biotechnology and life science industry of private and public companies. She joined Immunocore as Chief Business Officer and Board Director in May 2013. Since then Immunocore has established four pharmaceutical discovery partnerships.

Eva-Lotta was previously at Ablynx, serving as CBO for almost seven years and held roles in biotech companies including Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals.

Davidson Ateh CEO, BioMoti Davidson Ateh is a health entrepreneur. He is a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship and has a successful track record of financing disruptive ideas and progressing new technology. He is the CEO of BioMoti that is seeking to transform the treatment of cancer using its precision immunotherapeutic nanomedine platform: Oncojans™. BioMoti candidates have the potential to be ground-breaking cancer therapies for patients in need.

Graham BallProfessor of Bioinformatics, Nottingham Trent University and CSO of CompanDX and CompanDX(Wuhan) Prof Graham Ball is Professor of Bioinformatics at Nottingham Trent University and CSO of CompanDX Ltd and CompanDX(Wuhan) Ltd. He is Associate Director the John Van Geest Cancer Research Centre and biostatistics lead on three clinical projects. He has been involved in the development and validation of biomarker discovery algorithms using Artificial Neural Networks for the last 20 years. After a PhD (UN funded) and a Post Doc modelling pollution and plant environmental interactions with ANNs at NTU, in 2000 he shifted the focus of his analysis to proteomic and genomic data searching for proteins and genes associated with cancer and infectious diseases. His current research interests are directed at the classification and characterisation of biological systems including diagnostic and classification modelling of microbial pathogens, cancer clinical pathology, allergic responses and viral diseases through the use of ANNs and other machine learning techniques.

Laurence Barker Head of Investment Management, GSK Laurence is Head of Investment Management in the Worldwide Business Development team at GSK. Laurence is responsible for managing GSK’s venture investment portfolio and relationships with key partners including Index Ventures, and SV Life Sciences with regard to the recently launched Dementia Discovery Fund. In addition, he leads licensing transactions for the pharma R&D business. Prior to GSK, Laurence worked in business development at biotech companies Syntaxin and MorphoSys. Laurence holds an MBA from Cambridge and a PhD in Biochemistry from the University of Tuebingen.

8 speaker profiles

Michael Barnes Director of Bioinformatics, William Harvey Research Institute and Co-Investigator, MRC Farr London, Queen Mary University of London Michael Barnes holds a Biology BSc and PhD. in Molecular Genetics from Cardiff University. In 1997 he joined the new Bioinformatics team at SmithKline Beecham (later GSK), to mine the outputs of the nascent human genome project. At GlaxoSmithKline he led a computational biology team focused on the application of genetic, genomic and chemogenomic approaches to drug discovery and patient stratification. A strong advocate of pre-competitive collaboration among pharma and closer collaboration with academia, Michael co-led an EFPIA team to gain EU-IMI funding for the OpenPhacts IMI project (www.openphacts.org), which constructed an open tool box of chemo- and bioinformatics tools. After fourteen years at GSK, he co-founded Open Innovation Pharma Partners, with Prof Jackie Hunter, CBE. Michael joined the William Harvey Research Institute in 2012 as Director of Bioinformatics. Michael is a co-investigator at the MRC Farr London. His team are working across diverse domains, including genomics, drug discovery, stratified medicine and health informatics with a unified objective to drive forward translation into the clinic.

Michael serves on several project and advisory boards, including the MRC-eMedLab HPC facility, the IMI etriks project, IMI OpenPHACTS and the F1000 faculty (Bioinformatics). He has published widely and also edited the successful John Wiley Book, Bioinformatics for Geneticists. He holds a visiting Senior Lecturer post at the Institute of Psychiatry, Kings College London.

Steve Bates CEO, Bioindustry Association (BIA) Since his appointment as Chief Executive of the Bioindustry Association in 2012, Steve Bates has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors.

Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society’s Science, Industry & Translation Committee.

Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations.

An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years.

9speaker profiles

Morris Berrie Co-Chairman, TTS Global Initiative Dr. Morris S. Berrie is Co-Founder/Chairman of the TTS Global Initiative and a Director of Tech Investor. TTS is an organization that globally facilitates business understanding and consequently deal flow in the early stage start-up / SME biotech sector. TTS is currently involved in two EU Horizon 2020 projects. Tech Investor specifically consults for and advises companies on business development, strategy, licensing and capital raising.

Previously Dr Berrie was both the CEO and Editor-in-Chief of the Biotechnology Investment Group; Head of Global Intelligence and Business Development for Nature Publishing Group; Director of the Investigational Drug database (IDdb) at Current Drugs (now Thomson Reuters Pharma) and has worked at Schering AG and GlaxoWellcome. He is a Chartered Chemist (CChem), a Member of the Royal Society of Chemistry (MRSC) and was the recipient of a European DG Post-Doctoral Fellowship upon completing his Ph.D. at Imperial College, London. He is currently a Director of two Biotech start-ups, and additionally sits on the editorial board, business strategy and publishing committees of the Royal Society of Chemical Industry (Wiley).

Kate Bingham Managing Partner, SV Life Sciences Kate Bingham joined SVLS in 1991. Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Affinium, Alantos, Auxilium, Convergence, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, MedNova, Micromet, Oncoethix, PowderMed, RespiVert and Vantia and current investments including Atopix, Autifony, Bicycle, Calchan, Kalvista, Karus, Kesios, Pulmocide, TopiVert and VHSquared.

Kate has played an active role in setting up the new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee as well as the Investment Committees for al SV’s funds. Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA (Baker Scholar).

Aisling Burnand MBE CEO, AMRC Aisling’s role at AMRC is to champion the voice of the medical research sector, influencing the policy and research environment by harnessing the collective strengths of AMRC’s 139 members. Key to this is demonstrating the huge impact research charities have on health and wellbeing. Placing the voice of patients at the heart of medical research is vital in order to bring about change. Driven by a passion to make a difference, she took up the AMRC CEO role in Sept 2014.

10 speaker profiles

John Burt CEO, Abzena John has been CEO of PolyTherics since May 2011, having joined as Chief Business Officer in November 2011. In this time, the company has secured a licence agreement with Nuron Biotech for the development of TheraPEG interferon β, closed a £2.75 million funding round, expanded the application of the company’s technologies into the antibody-drug conjugate field and broadened the offering through the acquisition of Warwick Effect Polymers.

Prior to joining PolyTherics he co-founded Thiakis, with Professor Steve Bloom (Imperial College), which he led as CEO through a major financing round in 2006 and ultimately to its sale to Wyeth in 2008. John previously led medical and life sciences technology transfer for Imperial Innovations, responsible for a range of licensing transactions and was involved with a number of spin-out companies including as a board director of Sterix through the acquisition by Ipsen.

His career started as a management consultant with Coopers & Lybrand before entering the pharmaceutical industry with Vanguard Medica and then moving to GSK for a variety of technology licensing, predictive medicine strategy and corporate development roles.

John holds an M.A. (Natural Sciences) from University of Cambridge and a D.Phil (molecular biology) from University of Oxford.

Mark Carlton President and CSO, Takeda Cambridge Mark is President and CSO of Takeda Cambridge (TCB), Takeda’s discovery research operation in the UK. TCB focusses primarily on CNS diseases but also covers CV/Renal and some GI related areas. TCB arose from Takeda’s acquisition in 2007 of Paradigm Therapeutics, a biotech spun out of the University of Cambridge by Mark in 2001. Mark gained his PhD in Genetics from Cambridge, under Prof. Sir Martin Evans, where he also continued his academic studies.

Sue Charles Managing Partner, Instinctif Partners Sue has been providing communications counsel in the biotech sector for some three decades, supporting companies at the interface of innovation and wealth creation. She specialises in supporting clients operating across International borders, with significant experience in game-changing technologies. An entrepreneur and business leader, she has founded and led three consultancies, executing on investment and M&A transactions, as well as biotech CEO, non-executive and trustee experience. She holds a First class degree in Biochemistry from Oxford and an MBA from Cranfield Business School.

11speaker profiles

@EuroMed_Awards #MediscienceAwards Search: European Mediscience Awards

THURSDAY 9 JUNE 2016

THE BREWERY, LONDON EC1

SAVE THE DATEWWW.MEDISCIENCE-EVENT.CO.UK

The European Mediscience event is integral to the progress of Europe’s Life Science sector and you can be part of this prestigious event in the following ways:

o Host a table of ten at the event (subject to availability)

o Advertise in the brochure that is distributed to all 500 attendees

o Sponsor an award or the menu (subject to availability)

o Nominate a client or company (self nominations are also welcome)

o Participate in the marketing and PR campaign

www.mediscience-event.co.uk

7 MARCH 2016 NOMINATIONS OPEN

15 APRIL 2016 NOMINATIONS CLOSE

5 MAY 2016 THE VOTING PANEL MEETS

6 MAY 2016 SHORTLIST ANNOUNCED

9 JUNE 2016 AWARDS DINNER

AT THE BREWERY, LONDON EC1

Some of our sponsors and associates:

Renata Crome Project Leader, Cancer Research UK Renata started her career in academic research at St Thomas’s Hospital, London working on cardiovascular metabolism, cardiac arrhythmias and heart transplants .

She joined the Dept. of Cardiovascular Pharmacology at Roche gaining >25 years extensive experience in the scientific and clinical development, regulatory approval and commercialisation of new medicines.

Renata has spent the majority of her pharmaceutical career in early development, as Clinical Pharmacologist in the CVS, Infectious Diseases, and CNS therapeutic areas , then leading the Clinical Pharmacology Operations group, responsible for delivery of all the Roche Clinical Pharmacology Programmes.

As a Project Leader, she led project teams across a broad spectrum of therapeutic areas at all stages of development from the early discovery phase to life-cycle management for Roche’s key projects including Tamiflu the influenza drug , Avastin and Obinutuzumab Oncology molecules . Renata’s most recent role was global head of Early Development Clinical Operations and Deputy Head of Early Development at Roche.

She moved to join Cancer Research UK in early 2015 , to contribute her extensive knowledge of drug and particularly Oncology drug development to support the CRUK drug development programmes and heads up the study , project and portfolio management group.

Astrid Maria Dahl Executive Business Development Director - Oncology, AstraZeneca Astrid Maria Dahl is Executive Business Development Director, Scientific Partnering & Alliances – Oncology at AstraZeneca, a global pharmaceutical company operating in more than 100 countries worldwide. In this role she is responsible for global licensing and partnering with regards to oncology assets in early clinical development and research. Maria has a dual technical and business background and more than ten years’ experience in the US and UK biotechnology and pharmaceutical industry, primarily in the areas of business development and portfolio management.

Following a Ph.D. in Tumor Immunology from the Imperial Cancer Research Fund/University College London in the United Kingdom, she did her post-doctoral work in immunology at Harvard Medical School in Boston, USA. She then obtained an MBA from the University of California at Berkeley and moved into industry. She initially worked in the business development team at the San Francisco based biotechnology company Cell Genesys prior to moving to London to work for IPSEN from 2004 to 2012. At IPSEN she was responsible for oncology in the corporate business development team prior to being promoted in 2008 to Vice-President to head the entire oncology portfolio management team. She joined AstraZeneca’s business development team in early 2012 and is based in the offices in Cambridge, UK.

Jane Dancer CBO, F-star Jane Dancer is Chief Business Officer at F-star having joined the company in April 2012. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)) Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd,. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge.

13speaker profiles

Chris Farmakis EC Fund Manager, GLE Group Chris is working for GLE Group, an economic intervention organisation headquartered in London with nationwide coverage in the UK and operational branches in Prague and Brussels. His role is provide support for capital functions (funding and private finance) under Enterprise Europe Network for London. He has overseen over £60m worth of private capital transactions in the form of equity investments in SMEs and more than £250m worth of debt structuring. Since 2008 more than £25m worth of grant funding (FP7, TSB, NESTA, Welcome) has been awarded to London SMEs through EEN support.

Kieron Flanagan Senior Lecturer in Science and Technology Policy, Manchester Institute of Innovation Research Kieron is Senior Lecturer in Science and Technology Policy at the University of Manchester’s Manchester Institute of Innovation Research. He has worked in the area of science policy for more than 15 years, focusing on funding policy, research infrastructure, research performing organisations and the internationalisation of science. He has worked extensively with and for policy-makers in the UK and beyond. He blogs about science policy for The Guardian’s “Political Science” blog and tweets as @kieronflanagan.

Sally Ann Forsyth CEO, Norwich Research Park Sally Ann’s role is to create a supportive environment for innovation and develop Norwich Research Park as a world class science park.

Previously Sally Ann was Director of Science Parks for Goodman International responsible for development of Harwell Oxford and Colworth Science Park. A former Principal with Unilever Ventures, Sally Ann focused on technology spin outs.

Sally Ann holds a PhD in molecular biology from the University of Cambridge and is a qualified management accountant.

Flic Gabbay Founder and Partner, TranScrip Flic is Managing Partner of TranScrip of which she was a co-founder in 2008 and has worked in the pharmaceutical industry for more than 30 years. She has held senior positions in pharma and bio-tech companies in Europe and North America and worked on a range of products including small molecules and biologicals. She has been involved in registration programmes in US and Europe and launches of antibiotics, antifungals, respiratory, anti-inflammatories, lipid lowering agents, and anticancer including five she has worked on and defended within TranScrip. Previously Flic was a Regional Director of clinical research for Parke Davis and Head of Anti-infectives and she founded Gabbay Group, a CRO acquired by PPD where she became Global VP for Regulatory and Clinical Research. She was Founding Chairman of Phico Therapeutics and has also been CEO of two small biotech companies, Director of Education at the Drug Safety Research Unit in Southampton and Chairman of the steering group that set-up the UK Faculty of Pharmaceutical Medicine (FPM) and, for nine years, was its Academic Registrar.

14 speaker profiles

Leslie GallowayVice President, European Confederation of Pharmaceutical Entrepreneurs

(EUCOPE) Leslie built a successful career over 40 years in senior management roles in both the pharmaceutical and medical device industries, culminating in the successful turnaround of a pharmaceutical business.

He was elected EMIG Chairman in 2005 and has been instrumental in the metamorphosis of EMIG from being a business/networking group to the influential trade association it is today. In 2005, EMIG began with 17 Member Companies and today, has 240+, of which, 80% choose to be represented only by EMIG. Consequently, EMIG represents 40%+ of UK branded medicines.

In July 2014, Leslie was elected Vice President of EUCOPE. He was Vice Chairman of the NICE Project Development Group for Local Formularies Good Practice Guidance and a member of the NICE Medicines Optimisation Guidance Development Group. He is currently a member of the Accelerated Access Reference Group and a member of the Cancer Drugs Fund Working Group. He is a Member of the NHS-Industry Council, a Member of the Scottish Government’s Strategic Engagement Group, a Member of MENSA and is a visiting lecturer at the University of Cambridge.

Hakan Goker Senior Investment Director, MS Ventures

Hakan GokHa(Ph.D.) is a senior investment director at MS Ventures, the corporate venture capital fund of Merck Serono. Hakan joined MS Ventures in 2013 and previously was investing as a partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Orphazyme (DK), F Star (NL), Bicycle Therapeutics (UK), Nimbus Discovery (US) and Nitec now Horizon Pharma (CH/US). Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/Royal Marsden Hospital. He gained his BSc Honours, from University College London. Hakan is a board member of Asceneuron, Forendo Pharma, Raze

Therapeutics Therapeutics, Tocopherx, Synaffix, and Progyny Inc.

Melanie Goward Deputy Fund Manager, Finance Wales Technology Venture Investments Melanie is a Deputy Fund Manager with Finance Wales Technology Venture Investments. She manages an investment team targeting IP-rich high growth potential companies software, life sciences and medical technologies sectors and works with a portfolio of technology companies to support their growth and development. She was previously an Investment Director at NESTA, a London based technology seed fund. Melanie started her career in technology sector finance at Lloyds TSB Corporate providing debt finance to high-growth companies.

Melanie has a PhD in Genetics from Cambridge University, where she completed research forming part of the Human Genome Project. She also has a BA (Hons) in Natural Sciences.

Lars Gredsted Senior Business Analyst, Wellcome Trust Lars Gredsted is a Senior Business Analyst at the Innovations division at the Wellcome Trust in London where his responsibilities include sourcing of new investment opportunities, contract negotiations and management & oversight of funded projects/companies including board level representation. Lars previously worked in biotech with in-licensing of early stage research projects at and as management consultant with BCG. Lars gained his PhD from EMBL/Heidelberg University in addition he holds an MPhil in Bioscience Enterprise from Cambridge University and a Master of Biochemistry from the University of Copenhagen.

15speaker profiles

Eva Haas Senior Consultant, Investor & Public Relations, Hume Brophy Eva Haas is responsible for Investor Relations and Public Relations in Hume Brophy’s varied International Healthcare Practice serving companies large and small. She has 20 years’ experience in fund management and equity analysis of companies across the global healthcare sector. Most recently she was at Schroder Investment Management for 13 years, of which 7 were in New York, where she was responsible for the analysis and valuation of publicly listed & about-to-be-listed healthcare companies in the USA. Eva has a PhD from Bristol University. She is also a fluent German speaker.

Simon Haworth

Entrepreneur Dr Simon Haworth is an entrepreneur who spends most of his time engaging with China and his family has been trading with China for 6 generations. Simon established a Chinese subsidiary for bioinformatics company CompanDX in Wuhan, Hubei Province in 2013, began in-licensing UK pharma assets for development in China through Dynasty Biotechnology in the same year and has now established The Sino-UK Fund designed specifically to invest Chinese capital to European healthcare and cleantech projects.

Sarah Haywood COO, MedCity Sarah Haywood became Chief Operating Officer of MedCity in October 2014, after fulfilling the role in an acting capacity since its launch in April 2014 alongside her position as Head of Life Sciences at London & Partners.

She is a graduate of the NHS Management Training Scheme in Wales and started her career in the NHS, working in a number of NHS Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as the Head of Operations for a neuroscience drug discovery unit, located on the UCL campus.

From there, Sarah joined the civil service and undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. In January 2014 she joined London & Partners where she worked with Dr Eliot Forster to establish MedCity.

Sarah has a degree in Biology from the University of Oxford, a post graduate diploma in management and an MA in human resources management; she is a chartered fellow of the Chartered Management Institute.

Christian Hill Managing Director, MAP BioPharma Limited Christian Hill is Managing Director at MAP BioPharma and a Director of MAP MedTech and MAP Market Access. MAP provides market access guidance for biotech, pharmaceutical, medical device, diagnostics and vaccines businesses in the Europe and beyond.

Christian has over 18 years of experience in the life sciences industry, holding senior market-access-related positions at companies including Genzyme, Pfizer, Gilead Sciences and InterMune. He also serves on the board of EUCOPE, an EU trade organisation.

16 speaker profiles

Jackie Hunter CBE CEO, BBSRC Jackie Hunter is the Chief Executive of the BBSRC, the main funder of the UK’s bioscience research and training. BBSRC aims to promote innovation in the bioeconomy, fostering interactions, collaborations and technology transfer. BBSRC funds excellence in all areas of bioscience but also has 3 strategic priority areas, one of which is bioscience for health. Jackie’s background is in drug discovery and development and she has broad experience of industry-academia interactions.

Daniel Janse Senior Director of New Ventures, Johnson & Johnson Innovation Daniel is Senior Director of New Ventures at Johnson & Johnson Innovation, London. Previously, he was an Investment Manager at a life sciences VC fund, ran operations for a UK stem cell start-up and advised Top 10 Pharma on corporate, R&D and commercial strategy as a management consultant for McKinsey & Company. Daniel received his PhD in Biological Sciences from Harvard University and was a Presidential Fellow at the Novartis Institutes for BioMedical Research.

Rob Johnson Managing Partner, Alacrita Prior to co-founding Alacrita in 2009, Rob was Head of Business Development at Onyvax Ltd, a London-based biotechnology company developing complex biologics to treat cancer. At Alacrita, Rob focuses on helping companies with partnering and business development for first in class or best in class therapeutics and has ongoing engagements with Debiopharm and Bristol-Myers Squibb. Rob opened Alacrita’s US office in Cambridge, Massachusetts and has lived in the US since 2012.

Declan Jones Vice President, Neuroscience Lead, Johnson & Johnson London Innovation Centre Declan Jones, PhD is Neuroscience Lead at the J&J Innovation Centre in London. He is responsible driving drug discovery and development opportunities for Alzheimer’s disease and Mood Disorders from academic and biotech labs via direct collaborations, public-private partnerships, acquisition or investment by our corporate VC group, JJDC. Previously he spent 18 years in GSK in both internal and external drug discovery and development, finishing as Head of Research for the Centre of Excellence for External Drug Discovery (CEEDD).

17speaker profiles

Zahid Latif Head of Health & Care, Innovate UK Zahid’s first degree is in Pharmacy and after a year’s pre-registration training at the Glasgow Royal Infirmary, he gained membership of the Royal Pharmaceutical Sciences. He went on to study for a PhD in natural product chemistry aimed at the discovery and identification of insecticidal compounds from tropical plants. The PhD was sponsored by ICI and Zahid spent time working at the Jeallott’s Hill Research station in Bracknell.

After graduating Zahid worked for Xenova Discovery, firstly in Slough and later in Aberystwyth looking for novel plant secondary metabolites that could be used as tools for drug discovery. Following a management buy-out of the Aberystwyth labs, Zahid stayed on to work as Operations manager for the newly formed MNLPharma and took responsibility for the delivery of their compound library generation.

After 5 years in Aberystwyth, Zahid moved on to work for Wyeth as a clinical trials supplies pharmacist to gain a broader perspective of the drug development process. Prior to joining Innovate UK (formerly the Technology Strategy Board), Zahid worked for Integrin in Oban, one of the first marine biotech companies in the UK, heading up operations for 2 years. As well as looking after the research portfolio, Zahid was responsible for delivering the company’s algal toxin testing service which also included delivering a regulatory testing service for the Food Standards Agency in Scotland.

Zahid joined Innovate UK in October 2007 as Lead Technologist in Medicines and Healthcare and was promoted to Head of Healthcare in 2010.

Tom Lillie International Therapeutic Area Head for Oncology, Amgen Tom is responsible for oncology clinical research in Phase 2 – phase 4 for the European region and oversees the clinical teams for Amgen programs in oncology and haematology.

Dr. Lillie completed his undergraduate degree in pharmacology, cell biology and immunology at Brasenose College, the University of Oxford, before earning his doctorate from the Department of Physiology at the University College of London. He then completed his medical education at the University College London Medical School, receiving honors distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.

Dr. Lillie has held a variety of clinical research positions, specialising in oncology, in pharmaceutical companies in Europe and the USA.

Eddy Littler CEO, Domainex Dr Littler began his research career at the University of Leeds working with Ken Powell. After postdoctoral research at McMaster University in Canada and the Paterson Institute for Cancer Research in Manchester he joined the Wellcome Research Laboratories as Head of Herpes Virus Research. At Wellcome he became Head of the Gene Targets Group and following the acquistion of Wellcome by Glaxo he became Head of Antiviral Research at GlaxoWellcome.

Eddy left GSK in 2000 to join Medivir as Senior Director of Lead Discovery and Head of their UK operations. Whilst at Medivir he played a significant role in several deals, including the outlicensing of the HCV protease inhibitor (Simprevir) programme to Tibotec. The total value of deals converted at Medivir was $360M. Eddy became the Chief Executive Officer of Domainex in May 2008. Eddy

18 speaker profiles

consults for a number of companies and NGOs.

Karen Livingstone Director of Partnerships and Industry Engagement, Eastern AHSN Karen is Director of Partnerships and Industry Engagement for Eastern AHSN. Karen is also a National Director for NHS England, leading the Small Business Research Initiative (SBRI Healthcare). Karen was a Director of NHS Midlands and East and a non-exec director on the board of the East of England Regional Development Agency (EEDA) and Business Link East.

Formerly special adviser to the Secretary of State for Health, Karen has a background in communications and media.

Tim Luker Senior Director, External Innovation, Eli Lilly Tim leads Lilly’s external advancing innovation process in Europe within Global Corporate Business Development. Tim interacts with external VC funds targeting transformational early stage research across multiple therapy areas that work with Lilly and also supports general due diligence and search and evaluate initiatives.

He is an experienced drug hunter with 16 years’ experience and is an inventor / author on >50 patent applications and publications. He has worked in spin out biotech as well as roles at Shire pharmaceuticals (Director Exploratory projects, 2011-2014) and AstraZeneca (several R&D and medicinal chemistry roles, 1999-2011), leading multiple drug discovery projects through to candidate molecules as well as providing input into early development projects and managing medicinal & computational chemistry teams.

Tim has a PhD (1995) in chemistry from the University of Southampton, carried out post-doctoral research at Universiteit Van Amsterdam (1996-1999) and is also a Prince2 qualified project manager. https://uk.linkedin.com/in/timluker

Chris Maggos Managing Director, Europe, LifeSci Advisors Chris has over 20 years of experience in the life sciences industry covering investor relations, public relations, business development, journalism, investing, and molecular neurobiology. In September 2015 Chris opened, in Geneva, Switzerland, the European headquarters of LifeSci Advisors, a leading investor relations firm. Previously, Chris founded BioConfidant Sàrl a Geneva-based strategic consulting firm that helped senior executives achieve their financing and partnering goals.

At Addex Therapeutics (SIX:ADXN), Chris was a member of the executive management board and held the positions of Head of Investor Relations & Communication (2007-2010) and Director Business Development (2010-2013). He co-founded the Alpine Institute for Drug Discovery in 2013, a not-for-profit social enterprise whose mission is to help commercialize academic discoveries. Chris worked as: a journalist for the leading biotechnology trade publication BioCentury (2001-2007); an Associate at Casdin Life Science Partners (later Cooper Hill), a NYC-based biotechnology hedge-fund (1997-2000); and a molecular neurobiologist studying drug dependence at The Rockefeller University (1993-1997), where he co-authored twelve peer-reviewed publications. Chris holds a BA in English Literature from Yale University, where he also completed pre-medical studies

Keith Martin CEO, Apitope

19speaker profiles

Keith Martin, CEO of Apitope since 2006, has enjoyed a successful career in both large and early stage pharmaceutical/biotech companies holding senior positions in R&D and corporate & business development. He has both executive and non-executive Board experience with management and leadership roles in UK, Belgium, USA & Spain. He has raised more than € 40 million in equity and grants for early stage companies and has developed products from bench to market as well as closing significant licensing deals. He has also advised on venture investments

Chris Mayo Consultant - Primary Markets, London Stock Exchange Group Chris provides guidance to technology and life science companies and their shareholders on financing strategy. He has more than 17 years of corporate finance experience in New York and London for Barclays de Zoete Wedd, Citi and Schroders and has worked on more than 40 M&A, equity and debt transactions. Prior to his consultancy role at LSE, Chris spent 3 years as an investor and Head of Strategy for an early-stage cloud networking technology company. Chris holds a First Class Honours Degree in International Business and German from Aston University, a Masters in International Affairs from Columbia University and is a CFA Charterholder.

Stephen Minger Director, SLM Blue Skies Innovations and Senior Consultant, GE Healthcare Dr Stephen Minger was appointed the Global Director for Research and Development for Cell Technologies at GE Healthcare in 2009. Prior to this, he was the Director of the Stem Cell Biology Laboratory at Kings’ College London for 10 years. I

n 2013, Stephen was appointed Chief Scientist for GE Healthcare Life Sciences. He left full-time employment with GE in 2015 but is still a part-time Senior Consultant for GE Healthcare. He also serves as the Director of SLM Blue Skies Innovations Ltd, providing expert analysis in emerging healthcare technologies for the life sciences investment community. Stephen has a PhD in

Pathology/Neuroscience from the Albert Einstein College of Medicine.

Robert McMaster Chair of the Board, BC Clinical Research Infrastructure Network (BCCRIN)

Dr. W. Robert McMaster received a Bachelor and Master of Science from the University of British Columbia (UBC) that was followed by a D.Phil. from the University of Oxford. His research interests are in the areas of molecular immunology, parasitology and transplant immunology and is co-lead on a multi-million initiative “Biomarkers in Transplantation” with funding from Genome Canada/Genome BC and the Prevention for Organ Failure (PROOF) Center of Excellence Centre. He is actively involved with national and international granting agencies including the World Health Organization, Canadian Institutes of Health Research where he serves as the Scientific Officer for the Microbiology and Infectious Diseases Peer Review Grant Committee, and the Michael Smith Foundation for Health Research, having served as Chair of the Research Advisory Council. Dr. McMaster is a Professor in the Department of Medical Genetics and was Head of the Department, 2000-2010.

Dr. McMaster also held the positions as Director of the Immunity and Infection Research Centre at Vancouver Coastal Health Research Institute (VCHRI) and Director of Transplant Immunology for British Columbia Transplant, and was appointed the Vice President Research Vancouver Coastal Health, Executive Director, Vancouver Coastal Health Research Institute, and Associate Dean of Research, Faculty of Medicine, University of British Columbia in 2010.

Dr. McMaster is currently Chair of the Board for BC Clinical Research Infrastructure Network (BCCRIN), a member of the Health Research Council of BC, a member of the National Steering Committee for the CIHR Strategies on Patient Oriented Research, a member of the Board of Directors of Transplant Research Foundation of BC and has recently been appointed as the Vice Chair of the Board for Research Canada.

20 speaker profiles

David Parfrey Executive Director, Finance and Campus Operations, BBSRC David has very strong interests in improving impact from investment in research, particularly in capabilities available to researchers, and in encouraging early stage bioscience businesses in the UK. He is active in the development of Innovation Campuses at BBSRC sites across the UK, and holds Non-Executive Directorships in two Campus operating companies. David is the Non-Executive Chair of a company exploiting a ground breaking new plant science technology developed in a BBSRC sponsored Institute, and is a Non-Executive Director in a company underpinning an exciting new Institute under development.

David holds Fellowships of: Chartered Institute of Management Accountants; Royal Society of Biology; and the Institute of Directors.

Siro Perez Managing Director, Roundcape Siro has over fifteen years of scientific and international management experience across the whole research, development, commercialization, and investment process in new technologies.

Siro is Co-Founder and CEO of Molecular Warehouse, an mHealth molecular diagnostics platform. Siro also actively advises and co-founds start-ups through Roundcape, a boutique advisory firm, and is a Venture Partner at Hadean Ventures, a life sciences venture capital fund.

Previously, he served as CEO of ToxiMet, leading the company from a development stage start-up to a fully commercial enterprise with sales in 5 continents, and raising £5m at increasing valuations in the process.

Before joining ToxiMet, he worked investing in pharmaceutical and biotech stocks for one of the world’s leading hedge funds ($14B under management), and as Investment Manager for a global life sciences venture capital fund ($1.5B under management).

Prior to his investment career, he worked as Project Leader in the Zurich office of The Boston Consulting Group, managing strategy projects for global Pharma, Biotech, and Financial Services companies. Prior to that, he led a group in drug development and conducted research in neurodegenerative diseases at Novartis, and started his scientific career at the Cajal Institute of Neurobiology, with several publications in peer-reviewed journals.

Siro holds a Masters in Finance from the London Business School, and a PhD summa cum laude in Molecular Biology and a MSc in Chemistry with honours from the Autonoma University of Madrid. He also studied Computer Science Engineering at UNED, and speaks English, German, and Spanish fluently.

David Phillips Vice-President and Partner, SR One David joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. David brings a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. David has significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful

21speaker profiles

businesses deriving healthy exits for investors.

David has a BSc (Hons) in Pharmacology from the University of London and is a member of the Charted Institute of Marketing. David is based in London

Martino Picardo CEO, Stevenage Bioscience Catalyst Martino is the CEO of the Stevenage Bioscience Catalyst the UK’s first Biomedical Open Innovation campus. Martino has a PhD in Biochemistry from Cardiff University and spent 4 years at Baylor College of Medicine, Houston, TX. In 2004, he became Managing Director of UMIC and MICL (University of Manchester Incubator) and was previously a Board member of UKBI.. Most recently, Martino has been appointed to the Life Science Wales Hub Board as a Non –Executive

Roberto Pierini Scientist , APCure Roberto is a cell biologist who joined APCure in January 2014. He is leading the research of new APCure products. Roberto has a 5 year postdoctoral experience in innate immunity and host-pathogen interaction, at the INSERM (Lyon, France). Previously he studied the autophagy induction by viruses at the UEA of Norwich (UK). Roberto obtained his PhD in cancer research at the IFR (Norwich), investigating the role of diet in the prevention of oncogenesis.

Richard Pye Corporate Development and Communications, Summit Richard joined Summit in 2004 as a Senior Scientist and was involved in the formative development of the Company. He subsequently moved into the corporate side of the business and currently has responsibility for corporate communications, investor relations whilst also being involved with general corporate development activities including Summit’s recent listing on NASDAQ. Richard has a broad range of experience and skills and these include the fundraising on AIM and NASDAQ, securing not-for-profit financing, and M&A and divestment activities. He holds a PhD in Organic Chemistry and prior to joining Summit was a Post-Doctoral Research Associate at The University of Oxford.

Rachael Ritchie Director of International Partnerships, Genome British Columbia Dr. Rachael Ritchie, Director of International Partnerships at Genome British Columbia, is an internationally trained scientist with two decades of experience in life science research and innovation. She has worked in America and in Europe, across disciplines and borders, supporting multidisciplinary partnerships the bring discovery research to application. From aquaculture to population health, Ritchie seeks to catalyze bioeconomy partnerships to improve the productivity, sustainability and competitiveness of individuals, businesses and communities.

22 speaker profiles

Naveed Siddiqi Partner, Edmond de Rothschild Investment Partners Naveed joined the life sciences team of Edmond de Rothschild Investment Partners in 2013. Most recently he was a Partner at Phase4 Ventures in London. Prior to this Naveed worked for Nomura Phase4 Ventures, Nomura International, EFG Corporate Finance, KPMG and as medical doctor in the UK’s National Health Service. He has 22 years of venture capital, investment banking, private equity advisory and accountancy experience in life sciences and other sectors. Naveed graduated in medicine from Guy’s and St Thomas’s Hospital Medical School at the University of London. Later, he also qualified as a chartered accountant from the Institute of Chartered Accountants England & Wales. Naveed has previously served or observed on several company Boards in both Europe and United States at Nomura and Phase4 Ventures. Currently, he sits on the board of Laboratoris Sanifit

Julie Simmonds Director, Equity Research, Panmure Gordon Julie joined Panmure Gordon in 2015 from Canaccord Genuity. Her research coverage focuses on small and mid-cap healthcare companies. Prior to that Julie worked at Piper Jaffray where she spent five years as a Senior Analyst in the No. 1 Extel rated healthcare team. Her research coverage included both small and mid-cap UK healthcare companies, including medical devices, biotechnology and services, and large-cap European stocks.

Julie has also held positions at Nomura and as Head of Life Sciences Research at Evolution Securities where she was an analyst from 1998 to 2004. Julie has a PhD in Microbiology from University of Kent at Canterbury. Prior to becoming an analyst Julie gained industrial experience in both Europe and the US.

Claire Skentelbery CEBR Claire Skentelbery has a PhD in biochemistry and for the last 15 years has worked in the communication of science and the creation of scientific networks across Europe. In 2003, Claire was part of the team that launched the Council of European BioRegions (CEBR), which is a network of clusters across Europe with the aim to defragment the cluster development and to connect SMEs between clusters on a global scale. Claire continues to manage CEBR, and networks clusters around the world.

In 2010, Claire also took on the role of Secretary General of the European Biotechnology Network (EBN), a network with the mission to build partnerships. With almost 2000 members, EBN works to build scientific partnerships across sectors and organisation types, with a strong focus on SME-driven collaboration for effective maturation of science, making use of collaborative funding as a tool to drive partnerships.

Clare Terlouw Managing Director, Corporate Broking and Advisory, Numis Securities

23speaker profiles

Clare has over 17 years experience in the healthcare industry including 11 years as a specialist healthcare banker. Clare advises growing life science and healthcare companies on a range of transactions including IPOs, secondary fundraisings, private placements and M&A. She has a particular interest in biotech, specialty pharma, medical devices and medical technology. Prior to joining Numis, Clare held positions at Peel Hunt and Nomura Code. She also worked as an orthopaedic physiotherapist for 4 years.

Ingrid Teigland Akay Managing Director, Hadean Ventures Ingrid Teigland Akay is a medical doctor, entrepreneur and investor with experience within healthcare, consumer goods and technology. As a medical doctor, she has a broad clinical background from general medicine and surgery, working internationally in both the public and private sector. As a venture capitalist, Ingrid has substantial experience from deal sourcing, investing, and supporting start-up companies globally in different phases of development, from R&D to commercial stage

Nicola Thompson Head of Office of External Drug Discovery, Roche Nicki is Head of Roche’s Office of External Drug Discovery, focusing on delivering preclinical assets to all of Roche’s therapy areas in partnership with early-stage Biotechs and entrepreneurs. In her previous role at GSK, she was Senior Director, Business Development for GSK’s Ceedd (Centre of Excellence for External Drug Discovery), complementing and innovating internal drug discovery and development through external partnerships. Nicki is an experienced drug discoverer in both large Pharma and Biotech settings.

Mark Thompson Partner, Sidley Austin Mark Thompson has over 20 years of experience advising clients on international M&A and private equity transactions. Recognized as a leader in his field by Chambers, Best Lawyers in the UK, The Legal 500 UK and London Super Lawyers, Mark has extensive experience advising clients making investments in the U.S., Western and Eastern Europe, Russia and the Middle East. He represents private equity funds with respect to their investment activity, as well as fund sponsors in the formation of those funds. The LMG Life Sciences Guide lists Mark as a “Life Sciences Star” for M&A and corporate and commercial work in the industry.

Mark Treherne CEO, UK Trade & Investment Life Sciences Organisation Dr Mark Treherne is Chief Executive of the Life Sciences Organisation, which was established by UK Trade and Investment (UKTI) to support overseas investment into the UK: from the earliest R&D collaborations through to clinical trials, commercial operations and partnerships. Mark now has over 25 years’ experience of commercialising R&D in public and private pharmaceutical and biotechnology companies.

Abel Ureta-Vidal CEO, Eagle Genomics With a scientific background in molecular biology and immune-virology including a PhD from the Pasteur Institute, France, Abel first mastered bioinformatics tools and code in the early 1990s whilst working on viral phylogenetic studies. After his PhD, he joined the effort at Genoscope (Evry,

24 speaker profiles

France) in ramping up the Human Genome Project, putting in place the automatic gene annotation system for human chromosome 14. In 2001, Abel moved to the European Bioinformatics Institute (EBI) where he led the Ensembl comparative genomics team until 2007. He founded Eagle Genomics shortly before graduating from the Cambridge Judge Business School MBA program in 2008.

Louise Ward Partner, Commercial Real Estate, Charles Russell Speechlys Louise is a Partner in the Commercial Real Estate department of Charles Russell Speechlys LLP. She handles a wide variety of matters, acting for a mix of investors, developers and corporate occupiers across a number of real estate sectors on work including sales, purchases, pre-lets and leases. Louise has developed particular expertise in advising new entrants to the UK real estate market, for both investment purposes and for their own occupational needs. In the Life Sciences Sector, Louise acts for BioMed Realty, L.P, owner of Granta Park in Cambridge.

Tom Weaver CEO, Congenica Tom is interested in applying ‘omics technologies to healthcare. Commercial - founded Congenica Ltd, a genome diagnostics company, in 2014 and was part of genomic start-ups Hexagen and Geneservice, both successfully sold to publically traded companies, including Incyte (NASDAQ) and Source Bioscience (LSE) where he served on the board as Commercial Director. Academia: MRC (Director), MRC LMB, University of Cambridge (NIH and WT Fellow), and University Wisconsin (PhD Oncology, BSc Mathematics, Biochemistry).

Robert Wilkinson Director of Cancer Research, MedImmune Dr Robert W. Wilkinson, Director of Cancer Research, MedImmune Ltd.Robert has over 20 years of experience in biotech/pharmaceutical industries, in both small and large molecule cancer drug discovery. He is currently Director of Oncology Research at MedImmune (Cambridge), the biologics arm of AstraZeneca, and is charged with the generation and delivery of new candidate biotherapeutics. His team, uses the latest therapeutic strategies (incl. antibody and protein based platforms, oncolytic virotherapy and oligonucleotides) and is focused on immunotherapies, as well as tumour targeted therapies (incl. antibody-drug conjugates). Molecules to come out of the group include the anti-PD-L1 antibody, Durvalumab (MEDI4736).

Tony Young National Clinical Director for Innovation, NHS England Tony has been a medical innovator and entrepreneur throughout his career. He has established four MedTech companies and raised over £5m in private sector financing for these. He has been a Consultant Urological Surgeon at Southend Hospital since 2007 where his specialist clinical interests include stone disease and laser prostate surgery.

In 2010 he was appointed as Director of Medical Innovation at the Postgraduate Medical Institute at Anglia Ruskin University. He is leading on research, development and commercialisation of new medical devices and developing new educational programmes in this area. Through his role at the PMI he has been instrumental in bringing together the partnership that forms the Anglia Ruskin MedTech Campus. This will become one of the world’s largest health innovation spaces and will help transform the UK MedTech sector..In addition to this in the last 4 years Tony has been a member of a number of committees/oversight/expert review/task and finish groups for the Department of Health, NHS England, Public Health England, NIHR and Essex County Council. This work has focused on helping to deliver innovation across the NHS.

In September 2014 he was appointed as National Clinical Director for Innovation at NHS England. In this role he provides clinical leadership and support in delivering improved health outcomes across the 5 domains of the NHS outcomes framework. In particular he is focussing on driving the uptake

25speaker profiles

09.00 - 09.15

09.15 - 09.40

10.55 - 11.00

09.40 - 10.05

10.05 - 10.55

11.00 - 11.30 Coffee break

11.30 - 12.30 Parallel Sessions I

Welcome from One NucleusHarriet Fear CEO, One Nucleus

Investing in Innovation

Winners and Losers in the Life Science Industry 2015

Plenary Panel Debate: Are Public Market Technology Transfer Funds Changing Innovation Funding?

Closing remarks from the Chair

Mike Ward SCRIP Intelligence and Datamonitor

Richard Mason Johnson & Johnson Innovation

12.30 - 14.00 Lunch

Westminster, 4th floor Moore, 4th floor Victoria, 2nd floor Albert, 2nd floor

Chair Mike Ward SCRIP Intelligence

Case Study Deals - Immunocore - Eli Lilly

PanellistsNaveed Siddiqi Edmund de Rothchild Investment Fund

Hakan Goker MS Ventures

Sue Charles Instinctif Partners

Chair Abel Ureta-Vidal Eagle Genomics

Technologies Empowering use of -omics for Data-driven Discovery and Validation

Chair Davidson Ateh BioMoti

Funding an Innovative Science Base

Chair Rob Johnson Alacrita Consulting

International Growth Strategies: North America

Panellists PanellistsRachael Ritchie Genome British Columbia Tom Weaver Congenica Michael Barnes The Farr Institute

Eddy Littler Domainex

Craig Tucker Pennsylvania Bio

Satu Vainikka Valirx

Jane Dancer F-Star

Eva-Lotta Allan Immunocore

08.00 Registration

08.00 - 09.00 Breakfast SessionsAlbert 2nd floor

12.40- 13.00 Introduction to the Life Sciences Organisation (LSO)Mark Treherne UK Trade & Investment Life Sciences Organisation

Zahid Latif Innovate UK

Jackie Hunter CBE BBSRC

Rob McMasterVCH Research Institute

Aisling Burnand MBEAssociation of Medical Research Charities

Astrid Maria Dahl AstraZeneca

Lars GredstedWellcome Trust

Chris Mayo London Stock Exchange

Chris Maggos LifeSci Advisors

09.00 Opening of Genesis Whittle, 3rd Floor

Panellists

Supporting Life Sciences in London, Oxford, Cambridge: A MedCity UpdateSarah Haywood MedCity

Albert, 2nd FloorGLE Briefing: Trends in Life Science Investment

Chris Farmakis GLE Group

Victoria, 2nd Floor

ChairEric Elenko PureTech

Tom Hinton SyndicateRoom

Speaker Panellists

12.40 - 13.30 Lunch Keynote Address and BioNewsRound Award

Chris Mayo London Stock Exchange

David Pinniger Ploar Capital

26 programme

14.00- 15.00 Parallel Sessions II

15.00- 15.20 Coffee break

18.15 - 19.15 Drinks reception

Westminster, 4th floor Moore, 4th floor Victoria, 2nd floor Albert, 2nd floorCase Study Deal - Mereo Biopharma - Novartis

Flic Gabbay TranScrip Partners

Funding, Developing and Launching New Antibiotics and Anti-cancer Agents

Morris Berrie TS Global Initiative University

Improving Market Access to Enhance Innovation Funding

Simon Haworth Dynasty Biotech

Can you Fund your Research with Chinese Capital?

Panellists

Panellists

PanellistsNicola Thompson Roche

Renata Crome Cancer Research UK

Richard Pye Summit

Christian Hill MAP BioPharma

Karen Livingstone Eastern Academic Health Science Network (EAHSN)

Graham Ball CompanDX

Stephen Minger SLM Blue Skies Innovation

Westminster, 4th floor Moore, 4th floor Victoria, 2nd floor Albert, 2nd floor

Chair Mike Warrd SCRIP Intelligence

Case Study Deal - Johnson & Johnson Innovation - Alligator Bioscience Pharmaceuticals

PanellistsMelanie Goward Finance Wales

Clare Terlouw Numis Securities

Siro Perez Roundcape

Chair Robert Wilkinson MedImmune

Future of Immuno-Oncology

Chair Steve Bates BIA

Generating an Infrastructure for Innovation

Chair Claire Skentelbery CEBR

International Growth Strategies: Europe

Panellists Panellists PanellistsTom Lillie Amgen

Roberto Pierini APCure

Namir Hassan Immunocore

Martino Picardo Stevenage Bioscience Catalyst Sally Ann Forsyth Norwich Research Park David Parfrey BBSRC

Kieron Flanagan Manchester Business School

Louise Ward Charles Russell Speechlys

Mark Craighead Redx Pharma

Keith Martin Apitope

Leslie Galloway EMIG

Speaker Tony Young NHS England

Mike Ward SCRIP Intelligence

Mark Thompson Sidley Austin

John Burt Abzena

David Phillips SR One

Shaun Grady AstraZeneca

Whittle

19.15 Close

13.20 - 13.40 Presentation of the BioNewsRound Award 2015

13.00 - 13.20 Lunch Keynote Address

Chair Mike Ward SCRIP Intelligence

Julie Simmonds Panmure Gordon

Ingrid Teigland Akay Hadean Ventures

Eva Haas Hume Brophy

Denise Scots-Knight Mereo Biopharma

David Colpman Colpman Consulting

Daniel Janse Johnson & Johnson Innovation

George Freeman MP Minister for Life Sciences

Speaker

Panellists

ChairChairChair

Kate Bingham SV Life Sciences

Tim Luker Eli Lilly

Declan Jones Johnson & Johnson Innovation

Mark Carlton Takeda Cambridge

Laurence Barker GlaxoSmithKline

Chair Panellists

15.20 - 16.00 Plenary Session - Introducing the Dementia Discovery Fund

17.15 - 18.15 SCRIP – One Nucleus Plenary Debate: Trends in M&A and their Impact

16.10- 17.10 Parallel Sessions III

Chair Panellists

Speakers

27programme

Brea

k O

ut S

essi

ons

Alb

ert

2nd

floor

Vi

ctor

ia

2

nd flo

or

Moo

re

4th fl

oor

Wes

tmin

ster

4

th fl

oor

7

Bio

Cafe

Whi

ttle

Flem

ing

Brit

ten

Sour

ceLo

unge

6 5 4 3 2 1

2221

1413

1218

1716

15

i

363534

39

3837

H1

H2

H3

89

10

4645

44

4342

41

2930

333231

2524

HS

40

26

2827

23

Cate

ring

Toile

ts

Fire

Exi

ts

Part

neri

ng

iH

elp

desk

Key

Part

neri

ng

Phot

os

Pi

PiPa

rtne

ring

des

k

19 20

The

Glo

bal C

lust

er

Hub

11

47

The

Farr

Inst

itut

e In

dust

ry F

orum

St Ja

mes

4th

floor

H8

H7

H4 - 6

H10

48

49

H9

H11H12

Lift

s

Lift

s

Lift

s

5051

52

Dig

ital d

eleg

ate

phot

o bo

ard

29

TranScrip PartnersGlobal DataPage, White and FarrerR.G.C.C. International Eagle GenomicsFahy Gurteen LaboratoriesBioHub Birmingham EnvigoLondon Bioscience Innovation Centre (LBIC)UK Trade & InvestmentLife Science Hub WalesSequaniNorwich Research ParkBio-Rad Abd Serotec Stockholm-Uppsala Life Science (SULS) BoydsSidley Austin LLPGovernment of South Australia Flanders Investment & TradeScottish Development InternationalAstraZenecaUMI3AbzenaFirst Sight MediaThe Farr Institute Industry ForumWorld Courier

ils IntelligenceERA ConsultingZyme CommunicationsJumpstartForrestersSCRIP Intelligence LillyAPLAvacta Life SciencesDora Wirth (Languages) LtdManchester Science Partnerships (MSP) New Scientist JobsPharmidexPharma PublicationsMathys & Squire LLPSyne qua non LtdNova Language Services LtdKISS Communications QuickSTATBridge PartnersIllingworth ResearchCanadian High CommissionUnited Life SciencesGLERIFT GroupCreative Places

1234567891011121314151617181920212223242526

2728293031323334353637383940414243444546474849505152

HSH4 - H6 H7 H8H9H10H11H12

H1

H2

H3

Source Lounge - MedCityICHP, UCLP, HIN AHSNs Guy’s & St Thomas’ NHS Foundation Trust SBRI HealthcareOxford AHSN King’s College London ImanovaImperial Clinical Trials Unit

Get Ready for JP Morgan 2016Hume Brophy Flight Centre Business Travel United Airlines BiopartnerEBD Group Preparing for Start-Up and High GrowthAgility Health TechMoore Stephens Penningtons Manches Global Regulatory Services Outsourcing R&D Hartswood Media Assay Depot

exhibitor list

At last year’s Genesis event we brought a new concept to our conference, called the ‘Genesis Fringe’. This arose because we were increasingly approached to ask if we could promote an event being delivered on the days either side of Genesis in order to capitalise on the opportunity of and for Genesis visitors being in London. The fringe proved such a success that we have brought it back for you for Genesis 2015.

This year we are supporting a number of events as part of the Genesis 2015 Fringe including:

genesis fringe events

DEC 01

UK HealthTech ConferenceOrganised by MediWales, SEHTA and GLA

DEC 01

Accessing US Capital In Life Sciences Organised by Sullivan & Cromwell LLP, London Stock Exchange, RBC Capital Markets and Clermont

DEC 03

London MedTech: Innovation and Investment Trends Organised by MedCity, SEHTA and GLA

DEC 09

Personalised Medicine - Putting patients at the centre Organised by Bristows

DEC 09

Cell Therapy Seminar at the Shard Organised by Maria-Joao Martins

DEC 09 Asia Pacific Life Sciences Clinic

Organised by UK Trade & Investment (UKTI) London

DEC 07

The Future of Healthcare Organised by London Business School

DEC 09

Getting it Right: The Role of Smart Technologies and Data Analytics in Patient Adherence. And Genesis Welcome Reception Joint Anglia Ruskin MedTech Campus – One Nucleus Seminar

If you are interested in promoting an event as part of the Genesis 2016 Fringe, please contact [email protected]

DEC 09

LES Young Members Event Organised by LES

Brea

k O

ut S

essi

ons

Alb

ert

2nd

floor

Vi

ctor

ia

2

nd flo

or

Moo

re

4th fl

oor

Wes

tmin

ster

4

th fl

oor

7

Bio

Cafe

Whi

ttle

Flem

ing

Brit

ten

Sour

ceLo

unge

6 5 4 3 2 1

2221

1413

1218

1716

15

i

363534

39

3837

H1

H2

H3

89

10

4645

44

4342

41

2930

333231

2524

HS

40

26

28

27

23

Cate

ring

Toile

ts

Fire

Exi

ts

Part

neri

ng

iH

elp

desk

Key

Part

neri

ng

Phot

os

Pi

PiPa

rtne

ring

des

k

19 20

The

Glo

bal C

lust

er

Hub

11

47

The

Farr

Inst

itut

e In

dust

ry F

orum

St Ja

mes

4th

floor

H8

H7

H4 - 6

H10

48

49

H9

H11H12

Lift

s

Lift

s

Lift

s

5051

52

Dig

ital d

eleg

ate

phot

o bo

ard

Preparing for Start-Up and High Growth Supported by Global Regulatory Services and Agility Health Tech

Critical to building long term success are solid foundations and robust strategies. Delegates are offered the opportunity to meet privately for:

• A free 30 minute private 1-2-1 clinic with experts from Agility Health to rehearse and critique the positioning and presentation of their business and product development strategy

• The opportunity to meet with Tax and Grant experts from Moore Stephens around available incentives and funding• The opportunity to meet with legal experts from Penningtons Manches• The opportunity to meet with Global Regulatory Services to discuss how to optimise their development pathway options

Companies represented in the Innovation Hub can be found at H2 and include: Agility Health Tech, Moore Stephens, Penningtons Manches and Global Regulatory Services.

Outsourcing R&D Sponsored by Hartswood Media and Assay Depot

Critical to an effective out-sourcing strategy is the ability to identify the right vendors and implement a robust and efficient procurement process.

One Nucleus together with Hartswood Media and Assay Depot have launched two major initiatives which aim to enable our members to meet these goals. Meet Hartswood Media and Assay Depot at H3 and find out more about these initiatives and what they can offer you.

Get Ready for JP Morgan 2016 Sponsored by Hume Brophy Supported by the Flight Centre

The week commencing 11 January 2016 is once again set to be a vital point of the year for Life Science companies and investors as they head to San Francisco for the JP Morgan and Biotech Showcase Conferences. One Nucleus and Hume Brophy are keen to ensure attending companies maximise the impact on their business by providing access to expertise, savings and connections to aid your preparation.Exhibiting at H1 delegates are offered the:

• Opportunity to have a free 30 minute private 1-2-1 clinic with Investor Relations experts from Hume Brophy to rehearse and critique your presentation ahead of JPM

• Opportunity to find out what One Nucleus members are saving on the flight and hotel costs via Flight Centre Business Travel and United Airlines

• Opportunity to hear about discounts on the delegate fee to attend EBD Group’s Biotech Showcase via BioPartner UK• Opportunity to find out how to leverage One Nucleus collaborations with key US clusters

32

The Source Lounge

H4 - H6 H7 H8

ICHP, UCLP, HIN AHSNs

Guy’s & St Thomas’ NHS Foundation Trust

SBRI Healthcare

H9H10H11

Oxford AHSN

King’s College London

Imanova

The Source Lounge at Genesis 2015 sponsored by MedCity is a dedicated space located within the Britten room packed with some of the key access points to the biomedical research, clinical excellence and funding sources available across London, Oxford and Cambridge. In the Source Lounge you will find representatives from all three of the London Academic Health Science Networks, and the Oxford area AHSN, alongside representative from leading organisations like Imanova, Guys and St Thomas’, the Imperial Clinical Trials unit and SBRI. The theme pulling all these together is maximising healthcare innovation through partnership and engagement. In addition we have three focussed business hubs, see below. This is a unique opportunity for all delegates to explore partnership opportunities, receive expert advice, have 1-2-1 clinics and find out about savings on out-sourcing, conferences and travel.

source lounge

Imperial Clinical Trials UnitH12

You command connections.The in-market resources that come with World

Courier’s unsurpassed knowledge, global reach and

flawless supply chain execution mean that whether

your product is going across town or across the

world, you can trust us with what matters most:

your commitment to improving global health.

Choose confidently. Choose World Courier.

Learn more at worldcourier.com.

195_Journal_Print_Ad_210x297_r1.indd 1 8/7/15 11:48 AM

34

Avacta Life Sciences Affimer® reagents are affinity proteins, based on a small protein scaffold engineered to bind with high specificity and affinity to a range of targets. With a 7 week custom service and an online catalogue, Affimers are used for various applications in diagnostics, drug/biomarker discovery, biotech R&D and as therapeutic agents.

avactalifesciences.comDan Gare, Senior Business Development [email protected]+44 (0)1904 217046Stand 35

astrazeneca.com Ayesha Bharmal Director, Business Development and Partnering [email protected] Stand 21

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

The Abzena group (PolyTherics, Antitope and PacificGMP) have established a suite of complementary technologies designed to assist in successful development of antibodies and proteins with enhanced therapeutic benefits. With specialties in site-specific conjugation technologies for ADC development, optimization of the therapeutic properties of biopharmaceuticals, immunogenicity assessment, antibody humanization and deimmunisation of therapeutic proteins as well as cell line development and GMP manufacturing for Phase I and II clinical trials. The group has built a global customer base, including the top 10 pharma, large and small biotech, and academic groups.

abzena.com Neil Butt, VP Business [email protected] Stand 23

APL is one of the leading Scandinavian contract manufacturers (CDMOs) with 550 employees and four sites, all located in Sweden. APL’s facilities are well suited for manufacturing niche products in commercial scale as well as clinical trial materials. We manufacture in cGMP grade facilities, which are regularly inspected by EMA, FDA, and customers corporate QA. APL develops and manufactures in most formulations, from aseptic sterile injection solutions to non-sterile capsules and semi-solids. We offer high competence and extensive resources for a broad range of chemical and microbiological analyses, as well as develop and validation of analytical methods according to ICH Guidelines.

apl.seMattias Nyström, Business Development [email protected] 34

exhibitors

AbD Serotec, a Bio-Rad company, is an expert manufacturer and supplier of antibodies for drug discovery, clinical diagnostics and academic research. Whether you need a ready-made product, a complex custom antibody generation project, or small to bulk manufacturing and purification services, we cater for all requirements. No other company can rival our unique custom recombinant monoclonal antibody service that generates highly specific, high affinity Fab antibodies with >90% success rates in only 8 weeks. We aim to help you reach your goals by providing the antibodies you need and a professional, long-term partnership for success. For further information visit www.abdserotec.com.

abdserotec.com Chris Bullion, Antibody Sales [email protected] 14

The BioHub Birmingham®Established in March 2015, The BioHub Birmingham® is the first purpose-built facility of its kind in the UK. Based within Birmingham Research Park, it forms part of a thriving community of entrepreneurial businesses and academic researchers, offering the best possible ecosystem to develop biomedical innovations. An impressive 4,500 sq.ft of biomedical laboratory space is shared by tenants, along with tissue culture rooms, microscopy lab, sterilisation equipment, and a cryogenic suite. Desk space is also provided, along with the business advice and guidance which will be critical as your ideas move from the innovation and research phases to become market-ready commercial products.

thebiohub.co.uk Helen Miller-Viney – Business Development Manager [email protected] +44 (0)121 4 15 8543Stand 7

35

Boyds was established in 2005 and provides a range of expertise and skills central to support the development of your pharmaceutical & biotechnology medicinal products and medical devices. We are based in the UK with offices in Cheshire and Cambridgeshire.Our consultancy services offer a cost-effective solution for those requiring expert assistance in order to expedite development, add value to their product and reach those milestones. We have expertise in the development and commercialization of medicinal products across a broad range of therapeutic areas.Professional Services• ProductDevelopment• RegulatoryAffairs• RegulatoryMedicalWriting• StatisticsandDataManagement• MedicalMonitoringSupport• BusinessSupport• Training• DueDiligenceActivitiesboydconsultants.comStand 16

exhibitors

Stand 52

Creative Places are property advisers working across the UK to help clients create business environments that enhance innovation.

News for 2016 is that we have agreed to work with MedCity on a Life Sciences R&D Demand Study, involving leading research institutions. We seek to understand what the sector most needs and guide on how opportunity can be increased. We encourage participation by businesses interested in working with others. We believe this can truly help the London, Cambridge, Oxford triangle. Please find our stand and join us.

Stand 48

Canadian High Commission. The UK is by far Canada’s most important commercial partner in Europe and the Commercial and Economic Division of the Canadian High Commission in London works with Canadian companies, research institutes and universities that are seeking market opportunities or commercialisation, licensing and R&D partnerships. We also offer confidential advice and service to British companies interested in investing in Canada or in finding Canadian collaborators.

Bridge Partners and Bridge Fibre are sister companies working together to provide first class IT services. Based in Cambridge with 15 years’ experience of delivering on our core values of Clarity, Partnership and Quality.

Bridge Partners are a trusted partner offering outsourced IT support. Our professional, friendly team delivers tailored services: from hands-on technical support to top-level strategy giving our client time to focus on their business goals.

Bridge Fibre is a fast-growing communications technology company delivering a range of ISP services designed for Business Parks & their tenants. We specialise in providing cost-effective, high-speed internet connectivity, IP telephony and hosted services.

bridgepartners.co.ukAlastair Mundell44+ (0)1223 750150Stand 46

Eagle Genomics accelerates the opportunities offered by genomics and new data generation technologies to address some of the world’s key challenges in healthcare, infectious disease, personalised medicine, livestock and crop development, food quality and production, green energy and water recycling.

eaglegenomics.comMichael Reynolds [email protected]+44 (0)1223 654481Stand 5

DWL combines specialist translation services for the life science, pharmaceutical, biotechnology, medical technology and medical device industries with in house medical expertise, a proven track-record of dedication to the field, and a strong commitment to quality and service.

DWL has over 50 years’ experience in providing global translation solutions and language consultancy, in the following specialist areas:

•RegulatoryAffairs•ClinicalResearch•MedicalResearch•MedicalPublishing•Manufacturing•MedicalDevices•Legal•MarketingCommunications

dwlanguages.comKim Shouler, Business Development [email protected] 36

36

Fahy Gurteen Laboratories is a histopathology service provider to biotech, academia and the NHS.With an extensive quality management system at the heart of everything we do, we supply an unparalleled service from routine histology to whole slide scanning and advanced automated image analysis. Fahy Gurteen R&D department also holds patents for a novel cell cycle cancer test with prognostic and predictive indications, for which we are actively seeking development partners.

fglabs.comDr Saroj Velamakanni, Principal Scientist & Research [email protected]+44 (0) 1223 205040Stand 6

The Farr Institute of Health Informatics Research comprises four nodes distributed across the UK and led from the University College London (Farr Institute @ London), University of Manchester (Farr Institute @ HeRC N8), Swansea University (Farr Institute @ CIPHER), and the University of Dundee (Farr Institute @ Scotland). With a £17.5m-research award from a 10-funder consortium, plus additional £20m-capital funds from the Medical Research Council, the Farr Institute aims to deliver high-quality, cutting-edge research linking electronic health data with other forms of research and routinely collected data, as well as build capacity in health informatics research. The Farr Institute aims to provide the physical and electronic infrastructure to facilitate collaboration across the four nodes, support their safe use of patient and research data for medical research, and enable partnerships by providing a physical structure to co-locate NHS organisations, industry, and other UK academic centre

farrinstitute.orgStand 25

ERA Consulting has served the biopharmaceutical industry for over 28 years, providing regulatory, strategic and technical guidance for the development of medicinal agents (>450 to date), including ATMPs (cell/tissue/gene therapies including stem cell therapies), recombinant protein/antibody therapeutics, vaccines, natural products and small molecules. Our expertise covers quality, nonclinical and clinical aspects, both from the regulatory and development strategy perspective. Our specialised international team of more than 30 full-time professionals includes consultants drawn from biotech, pharma, biomanufacturing, regulatory, translational medicine and academic scientific backgrounds to provide experienced support from product inception through development to commercialisation.

eraconsulting.comAdam Levy [email protected] +44 (0) 20 7510 0200Stand 28

exhibitors

Envigo, one of the world’s leading global contract research organisations, and products and services company, is dedicated to helping our customers achieve the potential of their products and enhance life through the development of new medicines, greater food production and a safer environment. We set the highest standards and offer a broad range of practical support, consultancy and problem solving, all of which can be tailored to meet your specific needs. With locations across the world, you will always have access to our experts when you need them.

[email protected] +44 (0) 1480 892 000Stand 8

Flanders Investment & Trade (FIT) is a governmental agency and part of the Belgian Embassy. With over 90 offices worldwide our core focus is to maximise business opportunities by working in the interests of both overseas and Flanders-based companies.Our services include helping UK-based companies to set up an office, finding a partner, establishing relationships and aiding with funding in Flanders.With top European universities, a world-class reputation in innovative research and pioneering life science hubs, Flanders is a prime location for bio-innovation. We can help if you’re looking to establish your European headquarters, partner with life science experts or explore further possibilities of research.If you would like to find out more about our services, please do not hesitate to contact our office in London or take a look at our website at www.investinflanders.com. investinflanders.comStand 19

firstsightmedia.co.ukMike Gilham, Sales [email protected] 072 8753Stand 24

First Sight Media. As a video production and streaming specialist, the professional team at First Sight Media have been delivering creative live events, training and promotional videos for over 20 years. Specialising in live and on-demand video streaming, communicating your message through us, over the internet has never been easier. We also offer the ability for you to enhance your conferences and webinars through our bespoke presentation software iPresenter, allowing you to deliver high definition video of your speaker simultaneously with their presentation slides online. Whatever your audience, we can offer a tailored solution to effectively communicate your message through creative multimedia. Visit our website to see examples and get in touch.

37

Health Industries South Australia guides the growth of the biotechnology and medical technology sectors in Adelaide, South Australia. A$3.6 billion has been invested in the new “Adelaide BioMed City” cluster which includes the South Australian Health and Medical Research Institute (SAHMRI), the new 800-bed Royal Adelaide Hospital, two new University buildings, and SAHMRI 2 which is planned to host Australia’s first proton therapy unit. Adelaide BioMed City will be the largest cluster of its type in the Southern Hemisphere, employing 8,000 staff, including 1,500 world class medical researchers. Fast approvals and generous R&D cash back incentives make Adelaide an ideal location for your next Clinical Trial.

healthindustries.sa.gov.au/Jason.Jason Cameron, Trade & Investment [email protected] 18

exhibitors

At Forresters, we provide clear, sensible and practical advice on intellectual property, including patents, trade marks, designs and copyright, in the UK and across the world.

We like to take a collaborative approach with our clients, drawing on their knowledge to ensure that we understand what they want to achieve. We look to deliver our guidance in plain, jargon-free language and are not afraid to recommend a particular course of action, if we think it is right for you. We have a well-established and sizeable life-sciences department, with extensive experience in getting and litigating patents in the UK and Europe.

forresters.co.ukCharlotte [email protected] 31

GlobalData is a one-stop solution for actionable insight into the pharmaceutical and medical device sectors. Together with the best team of researchers, analysts, epidemiologists and consultants, and an unmatched suite of proprietary databases, we provide high-quality, accurate and transparent insight that can help you achieve growth and increase business value.Our valuable research and consulting solutions ensure you stay at the forefront of the industry by integrating accurate market forecasts and healthcare analytics on the latest trends and developments. Among other benefits, our informed healthcare industry perspectives have assisted businesses based across the pharmaceuticals, biotechnology and medical equipment markets in making strategic decisions that have increased the value of their products and services.

Stand 2

Enterprise Europe Network is your gateway to competitiveness and innovation. The Network supports businesses to make the most of the opportunities in the European market. We help local organisations to find the right business partners, build their innovation capacity and meet their capital requirements.

Enterprise Europe Network is strong of approximately 600 business support organisations in 54 EU and non-EU countries, promoting international cooperation locally.Our services are specifically designed for Small and Medium-sized Enterprises (SMEs) but are also available to all businesses, research centres and universities across Europe.

een-london.co.uk [email protected] Chris Farmakis , EC Funding Manager Stand 50

ilsintelligence.com [email protected] Escudero, Partner at Insights in Life [email protected] Hurtado, Partner at Insights in Life [email protected] 27

Insights in Life Sciences (ilS) is a global Life Sciences consultancy firm, specialized in all existing Primary Research solutions (ilS SolutionsSM). It provides Life Sciences companies with unique access to a broad range of Life Sciences Experts recruited by pre-defined knowledge and compliance criteria. Through ilS Primary Research Solutions (including in-depth phone interviews, online surveys and expert onsite panels) companies can access remarkable insights directly from world´s top experts. Leveraging on these insights, ilS allow Life Sciences companies to create and execute optimal Pricing and Market Access strategies thus achieve a competitive advantage.

Illingworth Research is a full service clinical CRO with experience across all phases of development from Phase I / proof of concept studies to post-marketing studies for small molecules, biotechnology products, medical devices and diagnostics. With a network of clinical infrastructure covering most therapeutic areas varying from clinical research units, primary, secondary and tertiary care sites across Europe and with partners in North America and Australasia, Illingworth has the capability to deliver large multi-centre global studies on time and within budget. Illingworth Research also provides research nurses for patient homecare to support studies for optimisation of patient retention and compliance. Illingworth also offers a medical photography service.

illingworthresearch.comJohn Illingworth, Managing [email protected] 47

38

Jumpstart is a specialist R&D tax advisory firm. We work with all sizes of companies across all sectors, as well as with accountants, on all stages of their R&D claims. Clients appreciate how we minimise their time, risk and complexity through the process as well as maximising the compliance and value for them.Our success comes from our scientific and technical approach, and we use our own experts, including chemists, biologists, physicists, computer scientists and software engineers, all fully trained on HMRC legislation.Jumpstarts commitment to a premium proposition includes ISO 9001 Quality Accreditation, a significant contributor to our achievement of R&D Tax Advisory Firm of the Year.

jumpstartuk.co.ukRoss Leader, Client Engagement Manager [email protected] 30

exhibitors

The London Bioscience Innovation Centre. Owned by the prestigious Royal Veterinary College (RVC), The London Bioscience Innovation Centre is London’s premier incubator for life sciences, providing high quality laboratory, office and technical support to over 60 companies. LBIC is located next to the RVC and a short walk from St Pancras International, Eurostar and the Francis Crick Institute.The RVC provides a range of commercial services via “RVC Business” for biomedical companies looking to access technical and academic expertise. Our contract research unit covers routine animal husbandry and laboratory services through to full study and design management within regulatory and non-regulatory environments.

lbic.com Dr Ken Larkin, Chief [email protected] 691 1122Stand 9

The Life Sciences Hub is the nerve centre of a vibrant and prosperous Welsh Life Sciences eco-system and brings together academic, business, clinical and professional services and funding organisations to provide a commercially-driven melting pot of talent.By encouraging research & development, and providing access to finance and expertise, the Hub showcases Welsh Life Sciences globally for success in health and wealth.The Hub’s unique space is designed to the highest standards, stimulating collaboration, innovation and investment. By becoming a member of the Hub, organisations have a single access point to dedicated facilities, networking, advice, events, promotion and funding opportunities.

lifescienceshubwales.comLife Sciences Hub [email protected] 2046 7030Stand 11

KISS is the creative agency that clarifies the complex. We work with ambitious brands that passionately believe they can change the world and need an agency that can deliver.With specific and in-depth expertise in Healthcare, Science, Technology and FMCG our ability to cut through complexity and successfully deliver a single-minded proposition has been instrumental in us winning a fantastic range of blue chip, SME and disruptive start up clients.We are strategy led and successfully integrate advertising, branding and digital services, and in Life Sciences we work in conjunction with our partner Zyme Communications, specialists in Life Sciences PR and marketing.

kisscom.co.ukSimon Fryer, [email protected] 44

Stand 37

MSP is the largest science and technology park operator in the UK with 4 campuses across the North West and provides over 1m sq ft of specialist lab and workspace for life science businesses.We provide the right environments for innovation to flourish and have been supporting the growth of companies in life sciences and other sectors for 30 years. Our network of connections between innovators, thinkers, investors and entrepreneurs brings business and people together to transform ideas into commercial reality and we accommodate businesses at every stage of their lifecycle – from start-ups to EU HQs and international centres of R&D excellence.We are proud supporters of the Genesis conference as a vital way to raise the profile of the sector in the North West and provide a showcase for investment opportunities to drive future growth.MSP’s shareholders are Bruntwood Ltd, The University of Manchester, Manchester Metropolitan University, Central Manchester University Hospitals NHS Foundation Trust and Manchester, Cheshire East and Salford City Councils.

Since Eli Lilly and Company was founded more than 135 years ago, our mission has remained unchanged: Create high-quality medicines that make life better. Healthcare challenges are complex and the unmet need is great; we know we can’t do it alone. We must be innovative in our science and in our approach to partnerships to bring medicines to the people who need them.OUR GREATEST INTERESTS INCLUDE: Oncology, Neuroscience, Diabetes, Immunology, Biotechnology, Emerging Markets, Drug Delivery and Devices, Cardiovascular. We are passionate about engaging in innovative partnerships in any of these areas.OUR APPROACH HAS THREE CRITICAL COMPONENTS: COMMUNICATE: Hear your ideas, Share our interests, and Start the conversationEXPLORE: Dive into the science, strategy, and commercial potential of every projectCOLLABORATE: Integrate our collective strengths to shape the science to benefit patients.

Kerri Lawford, Administrator, Search and Evaluation, Corporate Business Development [email protected]+44 (0) 1276 483454 Stand 33

To join our community of collaborators call 0161 279 6969 or email [email protected]

Or to speak to us about new bio and life science lab and office opportunities at Alderley Park call Dr Chris Doherty, Site Director on 07770 640 757 or email [email protected]

At Manchester Science Partnerships, we provide the right environments for innovation to flourish. Be a part of Manchester Science Partnerships to benefit from:

• Over 1m sq ft of lab and office space

• Open innovation campuses

• Collaborative workspaces and communities

Our network of connections between innovators, thinkers, investors and entrepreneurs brings business and people together to transform ideas into commercial reality. We accommodate businesses at every stage of their lifecycle – from start-ups to HQs and international centres of R&D excellence.

NEW DEVELOPMENT AT ALDERLEY PARK NO.1 MSP CENTRAL CAMPUSMERESIDE CAMPUS – ALDERLEY PARK

Create.Connect.Collaborate.

40

Norwich Research Park is a vibrant community comprised of innovation led companies, 4 world leading science research institutes, the University of East Anglia and the Norfolk & Norwich Hospital. The key areas of focus are Med-Biotech, Food & Health, Industrial Biotech and Agritech. The Park provides a supportive environment for innovation and growth. Services address the needs of science based businesses and include clinical trials facilities, biorepository, shared laboratories, extensive genomics, proteomics & metabolite services. Facilities include both formal and informal meeting space, contemporary cafés, free wifi and ample parking. There is a range of cost effective accommodation options comprising offices and laboratories with flexible terms plus development land for further growth. Less than 20 minutes’ drive from Norwich International Airport and only 1 hour from Cambridge, Norwich Research Park is currently home to over 40 businesses and 3,000 researchers and clinicians.

norwichresearchpark.comKenny Lang, Business Development [email protected] +44 (0) 1603 673 671 Stand 13

New Scientist Jobs is a dedicated job site for science, technology, engineering and maths helping you to attract relevant and qualified candidates. As part of the New Scientist family, we can offer one essential platform for your recruitment messages online, in print and via social media.

Emily [email protected] +44 (0)20 8652 4444Stand 38

exhibitors

MedCity is bringing together the world-leading strengths of the London-Oxford-Cambridge golden triangle with four main priority areas:• Providingasinglebrandedfrontdoorfor industry and investors, supported by a connected concierge service• Knowingthemarketsotheregion’sofferfits with and supports global life sciences development• Fosteringanenvironmentthatsupportsand encourages entrepreneurialism• Promotingtheregiongloballyasaworld-leading centre for life sciences research, commercialisation and manufacturingMedCity was established by Mayor of London Boris Johnson with the capital’s three leading research and clinical institutions - Imperial College Academic Health Science Centre, King’s Health Partners, and UCL Partners – in April 2014.

medcityhq.com @[email protected] Haywood, Chief Operating OfficerStand HS

Mathys & Squire is one of Europe’s top Intellectual Property firms. Since our formation in 1910, we have been committed to building genuine partnerships with our clients. The biotechnology group at Mathys & Squire has an enviable record of success. Our patent attorneys hold a wide range of scientific degrees, and many hold further degrees and PhDs. Some attorneys have worked within multinational corporations, further enhancing our ability to maximise the value of our clients’ assets. Our commercial understanding helps us advise clients, ranging from spin-out stage to multi-million pound funding projects, and has helped us to secure innovative licensing deals. With offices in Cambridge, London, Manchester, Reading and York, we are well-placed to meet with our UK-based clients face-to-face, to help get the best out of their ideas.

mathys-squire.comCraig Titmus, Senior [email protected] 41

Nova Language Services: specialist in delivering workable solutions in translation.We are internationally recognised Life Sciences experts, with a global presence and a well-established reputation. Our services meet the quality standards required of even the most heavily regulated fields, such as clinical research and regulatory affairs. We have in-depth knowledge of all therapeutic areas and manage projects while paying close attention to specific needs and requirements. All this with the level of care and insight demanded by the most exacting of clients.Give us your words. We’ll turn them into solutions.

nova-transnet.comArun Mathew, Business Unit [email protected] 43

pagewhite.comStand 3

Established in 1875, Page White & Farrer is a leading UK firm of patent and trade mark attorneys. Our comprehensive services include assistance with invention capturing, filing and obtaining patents in the UK, at the European Patent Office and worldwide. We conduct European patent oppositions, advise on freedom to operate, and provide due diligence and portfolio services. We have a wealth of experience working with individual inventors, academic/research institutions, start-ups and other emerging entities. Our specialist team of life science attorneys are experts in providing legal, practical and strategic advice, translating your innovation into valuable business assets.

41

RGCC Pharma is one of the members of the RGCC group, is located in Bristol, UK, and holds all the rights of the new developed pharmacophore agents and candidate drugs. The company, in collaboration with the other members of the group, analyses multiple biological samples, identifies repeatable patterns of proteins that may be related with the disease development and validates them. According to the location of the drugable target the company will proceed to develop either of a monoclonal antibody or a small molecular weight organic molecule with inhibitory properties. So far the pipeline includes agents related to stemness as well as cancer cell metastases.

[email protected] Dr. Roger Oakes0044 (0) 1179058738, 0044 (0) 1172305034Stand 4

Scottish Development International is the economic development agency for Scotland and is a joint venture between the Scottish Government, Scottish Enterprise and Highlands & Islands Enterprise.Since it was founded 11 years ago, SDI has transformed Scotland’s economic outlook, attracting some of the world’s biggest companies to locate in the country, growing Scottish exports and creating over 19,000 new jobs.Scotland hosts one of the largest life science clusters in Europe with significant international presence in research, development and manufacturing. With a long and remarkable history of medical and scientific discovery stretching back 200 years, Scotland has always been at the forefront of medical innovation.

sdi.co.ukFiona Jefferson, International Senior [email protected] 20

exhibitors

For 35 years, QuickSTAT has managed clinical trial logistics in more than150 countries worldwide. With innovative solutions that offer complete end-to-end transportation services, your time and temperature-sensitive clinical research specimens, investigational drugs, and biologics are handled with unmatched attention, reliability and care.

[email protected] 45

Tagline font: Univers 57 Condensed Oblique

Red: PMS 185 CCMYK: 0.92.76.0RGB: 224.0.52HTML: E00034

Grey: PMS 431 CCMYK: 45.27.17.51RGB: 94.106.113HTML: 5E6A71

pharmidex.co.ukStand 39

Founded in 2002, Pharmidex is a CRO with extensive CNS drug discovery and ADMET/PK expertise. Pharmidex provides tailored studies critical to the progression of drug discovery programmes and research collaborations. Pharmidex has been able to deliver a high level of customer satisfaction and forge several strategic international alliances, focussing on operations in the following areas: in vitro ADMET, Pharmacokinetics, Pharmacology, CNS Drug Discovery, Bioanalysis, Metabolite Identification, and Toxicology. Pharmidex clients include Pharma, biotechs, governmental institutes, universities and medical charities. Pharmidex has also extensive experience in grant funded collaborations with numerous successful ongoing and completed projects.

Pharma Publications is a dynamic media organisation, specialising in publications for the Life Sciences Industry. With a portfolio of publications like, IPI (International Pharmaceutical Industry), JCS (Journal for Clinical Studies), JPC (Journal for Patient Compliance) and IAHJ (International Animal Health Industry) we inform the Pharmaceutical Industry on the best practice in outsourcing management. Providing peer reviewed articles and analysis on drug discovery, drug development, clinical research, manufacturing, packaging, supply chain management, patient adherence and health outcomes, we provide comprehensive guidelines to help the industry grow. We are your one-stop-shop for all your marketing to the pharmaceutical industry.

ipimediaworld.com, jforcs.com, jforpc.com, animalhealthmedia.com Orsolya Balogh - [email protected] 40

SCRIP is a leading source of news and strategic analysis for the global pharmaceutical industry. We filter the flood of information on the industry and apply the knowledge of our extensive network of analysts, journalists and key opinion leaders to provide our readers with timely business critical market and competitor intelligence.

scripintelligence.comStand 32

42

Tony Rees, [email protected]: +44 (0) 1379 644449www.synequanon.comStand 42

Syne qua non (SQN) is one of the largest functional Biometrics CROs in Europe providing global pharma, biotech, medical device and animal health partners with innovative, cost effective development services in eCRF/CRF design, data management, statistics, EDC trial management, ePRO, project management, quality management, consultancy and audits and medical writing. Our powerful, yet flexible, site-friendly EDC system can be rapidly developed delivering high quality data with real-time, drilldown reporting within a competitive pricing model. Working as if part of your team our can-do culture provides a service that is refreshingly different from other CROs.

TranScrip is a trusted partner in providing strategic leadership and operational capacity for over 100 companies across five continents. Our range of clients includes both biopharma SMEs and 20 of the top 50 pharma.TranScrip supports the development and lifecycle management of biopharmaceutical products. We provide expertise, resourcing and strategic oversight from translational medicine to successful registration and market access. Our range of services includes facilitating selection/progression of preclinical drug candidates through to POC, support for partnering exercises and throughout clinical development and registration. In summary, our talented, insightful teams help you maximise your opportunities, reduce risk and create value.

transcrip-partners.comStand 1

exhibitors

Sequani is a preclinical CRO based in Ledbury (UK) that has an international reputation for excellence in the field of toxicology. Established for over 40 years, with key areas of expertise such as First-in-Man (Phase I) enabling programmes, Reproduction Toxicology and Juvenile Toxicology, across many therapeutic indications and to support each stage of clinical drug development.

Being a small/medium-sized facility of approximately 180 people, we take a flexible and creative approach to drug development, working closely with our customers to design bespoke, tailored pre-clinical programmes to meet their specific clinical objectives.

sequani.comStand 12

Sidley Austin LLP is a premier law firm. Our global team provides strategic legal advice to businesses in the biotech sector, representing local clients in the UK, as well as international corporations and investors across Europe, the U.S. and Asia.

sidley.comMark Thompson, Partner [email protected]+44 20 7360 3730Stand 17

Stockholm-Uppsala is the country’s largest life science region, where business and research thrive. Our region is a hot-bed of creative cross-disciplinary collaboration and together, we build international businesses and deliver real research breakthroughs that help solve some of the world’s health problems. We are open-minded and productive. Our state-of-the-art infrastructure and talented scientists provide all the services and support you will need. Our companies are global from day one. Meet some of our companies represented at Genesis during breaks, at one-to-one meetings or in our booth. Or come by and talk to us about the assets of our region. We are happy to show our potential for business, collaboration and investments.

suls.seYwonne Bölja, Marketing [email protected] 15

UK Trade & Investment (UKTI) is the UK’s international trade and inward investment promotion organisation. We provide support and assistance to new and existing UK exporters of goods and services, and our network reaches over 100 markets overseas supporting businesses locally. We also lead an inward investment network including private sector expertise to help overseas-owned firms locate and build their business in and from the UK. UKTI’s Life Sciences Organisation (LSO) catalyses and coordinates life sciences trade and inward investment across the whole of the UK.

gov.uk/ukti/lso@UKTI_LSOStand 10

43

Stand 49

United Life Sciences is a strategic partnership representing over 1,000 life science and healthcare organisations across the UK and internationally. The ULS collaboration has member and the wider UK life science sector benefit at the heart of its purpose and is the basis for all joint activities. It strives to avoid duplication of effort and coordinates the five organisations’ activities whilst recognising each other’s areas of strength so that member companies can benefit from more effective and coherent sector support.

One Nucleus - Harriet Fear, [email protected]

BIA – Steve Bates, [email protected]

Bionow - Geoff Davison, [email protected]

BioPartner - Lin Bateson, [email protected]

MediWales - Debbie Laubach, [email protected]

UMIP® is The University of Manchester’s agent for intellectual property commercialisation. UMIP’s three operational teams: Scouting; IP Development and Partnering; and Enterprise and Business Development are responsible for identifying, protecting and commercialising the University’s IP. UMIC® is the University’s Innovation Centre-its bioscience incubators include the successful Manchester Bioscience Incubator and the Core Technology Facility (CTF). UMIC® also provides conferencing and meeting room facilities. UMIP® and UMIC® are divisions of The University of Manchester Innovation Group Ltd; www.umi3.com

umip.com [email protected]@umic.co.ukStand 22

Zyme Communications Ltd provides strategic and specialist communications services for the life science sector. Based in Cambridge and Manchester in the UK, and with clients across Europe and the USA, Zyme is focused on supporting companies to raise their profile and generate interest from commercial leads, investors and partners. With an international network of life science trade media contacts and a strong technical understanding, Zyme is committed to delivering value and results from objective-lead communications.

zymecommunications.com Lorna Cuddon, Managing [email protected]+44 (0)1223 968 920Stand 29

World Courier is a global specialty logistics company that designs world-classlogistics and supply chain programs in complete alignment with our customers’business goals. Pharmaceutical companies rely on us because they value thepeace of mind that comes with our unsurpassed knowledge, global reach andflawless supply chain execution. Each trusted partnership we form with a customeris deeply rooted in our shared vision of improving global health. With 2,000+associates in more than 140 offices across the globe, we offer solutions that instillconfidence in the on-time, on-temperature delivery of critical products. When trustis absolutely essential, there’s only one choice: World Courier.

worldcourier.com Stand 26

exhibitors

United offers unrivalled access to the U.S. with nonstop flights from seven U.K. airports, and onward connections to over 300 destinations across the Americas. With services from London Heathrow, Manchester, Birmingham, Edinburgh, Glasgow, Belfast and Newcastle, United offers nonstop transatlantic flights from more U.K. cities than any other airline. And you won’t just arrive: you’ll arrive refreshed, thanks to our superior levels of comfort and personal service. From extra legroom in United Economy Plus® to 180 degree flat-beds in United BusinessFirst®, air travel is a pleasure.

United.comDavid Davis, Corporate Account [email protected]

Life Sciences Hub Wales is the nerve centre of a vibrant and prosperous Welsh Life Sciences eco-system, it brings together academic, business, clinical, professional services, government and funding organisations to provide a commercially-driven melting pot of talent.

Designed to facilitate innovation and growth, the Hub hosts and engages Life Sciences organisations large and small. Member organisations and partners have a single access point to dedicated facilities, co-ordinated support, networking, advice, events, promotion and funding opportunities.

Tel: +44 (0)29 2046 7030

Email: [email protected]

lifescienceshubwales.com

Stand 11Meet the team

The route to new markets new funding new ideas

Go further, faster

www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512

Enterprise Europe Network London

INNOVATIVE SOLUTIONS FOR THE BIOTECH LANDSCAPE

Sidley is a leader in advising biotech innovators and investors

throughout the lifecycle of their products and investments. Working

seamlessly with the fi rm’s lawyers across the United States, Europe

and Asia, we help clients navigate the range of issues

inherent in the industry—from the science and technology

opportunities to the legal and business challenges.

TALENT. TEAMWORK. RESULTS.

Scott [email protected]+1 212 839 5613+1 202 736 8684

Coleen KlasmeierPartner [email protected]+1 202 736 8132

Maarten [email protected]+32 2 504 6467

Mark [email protected]+44 20 7360 3730

RECOGNIZED AS A LEADING LAW FIRM IN PHARMACEUTICALS AND BIOTECHNOLOGY

– THE LEGAL 500 UNITED KINGDOM 2015

Attorney Advertising - For purposes of compliance with New York State Bar rules, our headquarters are Sidley Austin LLP, 787 Seventh Avenue, New York, NY 10019, 212 839 5300; One South Dearborn, Chicago, IL 60603, 312 853 7000; and 1501 K Street, N.W., Washington, D.C. 20005, 202 736 8000. Sidley Austin refers to Sidley Austin LLP and affi liated partnerships as explained at www.sidley.com/disclaimer. Prior results do not guarantee a similar outcome. MN-2799

AMERICA • ASIA PACIFIC • EUROPE

sidley.com

Our translational research conference

Translating UK scientific excellence into global therapeutic strategies

onhelix.com

28 June 2016 Cambridge, UK

Our translational research conference

Translating UK scientific excellence into global therapeutic strategies

onhelix.com

28 June 2016 Cambridge, UK

C

M

Y

CM

MY

CY

CMY

K

20151002_EMEAI_BusinessFirstMagazine2 copy.pdf 1 02/10/15 12:47

handbook 2015 - genesis conference · laurence is responsible for managing gsk’s venture...

Documents